Boston MA 白血病临床试验
27项针对 白血病的研究正在 Boston及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
招募中3 期
- MGH, Boston
HEME Home Transfusion Program
招募中
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
招募中观察性研究
- Floating Hospital for Children at Tufts Medical Center, Boston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
招募中2/3 期
- Dana-Farber Cancer Institute, Boston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
招募中3 期
- Research Site, Boston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
招募中2 期
- Dana-Farber Cancer Institute, Boston
Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
招募中
- Dana-Farber Cancer Institute, Boston
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
招募中2 期
- Massachusetts General Hospital, Boston
CIML NK Cells With Venetoclax for AML
招募中1 期
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
招募中1 期
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
招募中1 期
- Beth Israel Deaconess Medical Center, Boston
ALL Backbone in AYAs
招募中2 期
- Dana Farber Cancer Institute, Boston
Addressing Cancer Care Equity With Social Determinants of Health Screening and Early Intervention
招募中
- Mass General Brigham Cancer Institute, Boston
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
招募中欢迎健康志愿者
- Dana-Farber Cancer Institute, Boston
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
招募中1 期
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
招募中1 期
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
招募中1/2 期
- Dren Investigational Site, Boston
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
招募中1 期
- Dana-Farber Cancer Institute, Boston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
招募中观察性研究
- Dana-Farber Cancer Institute, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
招募中
- Massachusetts General Hospital Cancer Center, Boston
Shwachman Diamond Syndrome Registry and Study
招募中观察性研究
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Revumenib in Combination With 7+3 + Midostaurin in AML
招募中1 期
- Dana-Farber Cancer Institute, Boston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
招募中1 期
- Massachusetts General Hospital, Boston
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
招募中1/2 期
- Dana-Farber Cancer Institute, Boston
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
招募中1/2 期
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Mosunetuzumab for CLL MRD Clearance
招募中1/2 期
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
招募中
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
其他城市的 白血病试验
- Houston, TX31 项研究
- New York City, NY21 项研究
- Chicago, IL19 项研究
- Los Angeles, CA17 项研究
- Durham, NC14 项研究
- Baldwin Park, CA14 项研究
- Nashville, TN13 项研究
- Columbus, OH13 项研究
- Philadelphia, PA13 项研究
- Atlanta, GA12 项研究
- Milwaukee, WI12 项研究
- Seattle, WA12 项研究
Boston的其他研究
- 乳腺癌110 项研究
- 癌症（所有类型）90 项研究
- 非小细胞肺癌87 项研究
- 肺癌63 项研究
- 结直肠癌62 项研究
- 卵巢癌62 项研究
- 转移性癌症61 项研究
- 前列腺癌56 项研究
- 子宫内膜癌51 项研究
- 抑郁症50 项研究
- 心力衰竭46 项研究
- 多发性骨髓瘤45 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年11月15日。每项研究自行设定入选标准，由研究团队决定谁能参与。